PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33440483-3 2016 Growth factor binding ability of the native sulfated glycosaminoglycans can be incorporated into the synthetic scaffold matrix through functionalization with specific chemical moieties. Glycosaminoglycans 53-71 myotrophin Rattus norvegicus 0-13 2607320-9 1989 Transforming growth factor beta (greater than 10 pmol/l) inhibited foetal calf serum (Dulbecco"s modification of Eagle"s medium with a fraction of foetal calf serum of 0.1) and epidermal growth factor stimulated proliferation but enhanced the synthesis of sulphated glycosaminoglycans about 2-fold. Glycosaminoglycans 266-284 myotrophin Rattus norvegicus 13-26 2607320-9 1989 Transforming growth factor beta (greater than 10 pmol/l) inhibited foetal calf serum (Dulbecco"s modification of Eagle"s medium with a fraction of foetal calf serum of 0.1) and epidermal growth factor stimulated proliferation but enhanced the synthesis of sulphated glycosaminoglycans about 2-fold. Glycosaminoglycans 266-284 myotrophin Rattus norvegicus 187-200 33662819-0 2021 Histologic evaluation of therapeutic responses in ischemic myocardium elicited by dual growth factor delivery from composite glycosaminoglycan hydrogels. Glycosaminoglycans 125-142 myotrophin Rattus norvegicus 87-100 33754692-0 2021 Injectable Glycosaminoglycan-Based Cryogels from Well-Defined Microscale Templates for Local Growth Factor Delivery. Glycosaminoglycans 11-28 myotrophin Rattus norvegicus 93-106